Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Cisplatin as First-Line Therapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Interventional
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary Objectives of the Study
To determine the safety of TLK286 in combination with cisplatin in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) To determine the MTD of TLK286 in combination with cisplatin in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
Every 3 weeks
Yes
United States: Food and Drug Administration
TLK286.2021
NCT00077883
February 2004
March 2007
Name | Location |
---|---|
The Sarah Cannon Cancer Center | Nashville, Tennessee 37203 |
Univ. of TX, MD Anderson Cancer Center | Houston, Texas 77030 |
Univ. of MD, Greenbaum Cancer Center | Baltimore, Maryland 21201 |